PUTRI TALCHA OKTAVIANY, - (2024) ANALISIS EFEKTIVITAS BIAYA TERAPI ANEMIA PADA PASIEN GAGAL GINJAL KRONIK DI UNIT HEMODIALISIS RSUD AL IHSAN PROVINSI JAWA BARAT. Skripsi thesis, Sekolah Tinggi Farmasi Indonesia.
![[img]](http://repository.stfi.ac.id/style/images/fileicons/text.png) |
Text
S_PSSF_A223011_Title.pdf Download (279kB) |
|
Text
S_PSSF_A223011_Chapter1.pdf Restricted to Repository staff only Download (83kB) |
|
Text
S_PSSF_A223011_Chapter2.pdf Restricted to Repository staff only Download (301kB) |
|
Text
S_PSSF_A223011_Chapter3.pdf Restricted to Repository staff only Download (129kB) |
|
Text
S_PSSF_A223011_Chapter4.pdf Restricted to Repository staff only Download (238kB) |
|
Text
S_PSSF_A223011_Chapter5.pdf Restricted to Repository staff only Download (7kB) |
|
Text
S_PSSF_A223011_Appendix.pdf Restricted to Repository staff only Download (1MB) |
Abstract
Angka kejadian Gagal Ginjal Kronik (GGK) di Jawa Barat menduduki urutan kedua tertinggi di Indonesia dimana anemia merupakan komplikasi yang terjadi pada 80-90% pasien gagal ginjal kronik yang menjalani hemodialisis, oleh karena itu perlu dilakukan analisis efektivitas biaya untuk memilih jenis terapi yang paling efektif dan efisien. Penelitian ini bertujuan untuk mengevaluasi perbedaan efektivitas dan biaya terapi anemia pada pasien GGK dan mengetahui regimen yang paling mempengaruhi efektivitas biaya pengobatan. Pengumpulan data dilakukan secara retrospektif berdasarkan catatan rekam medis dan rekap keuangan pasien di RSUD Al-Ihsan secara purposive non-random sampling pada periode Juli-Desember 2023. Analisis efektivitas biaya dilakukan dengan menghitung Average Cost Effectiveness Ratio (ACER), Incremental Cost Effectiveness Ratio (ICER) dan analisis sensitivitas. Hasil penelitian menunjukkan rata-rata kenaikan Hb kelompok pasien yang diberikan terapi transfusi darah lebih tinggi (7,28%) dibandingan kelompok Hemapo® (1,12%) dan Renogen® (1,70%). Nilai ACER pada kelompok transfusi darah lebih rendah dibandingkan kedua kelompok lainnya yaitu sebesar Rp 4.702.512. Berdasarkan nilai ICER kelompok Renogen® memiliki nilai yang lebih rendah sebesar Rp 38.572. Kesimpulan dari penelitian ini adalah bahwa transfusi darah merupakan kelompok terapi yang paling cost-effectiveness dan berdasarkan hasil analisis sensitivitas menunjukkan kelompok terapi Hemapo® menjadi regimen terapi yang paling mempengaruhi efektivitas biaya. ----- The incidence of Chronic Kidney Disease (CKD) in West Java is the second highest in Indonesia where anemia is a complication that occurs in 80-90% of chronic kidney failure patients undergoing hemodialysis, therefore it is necessary to analyze the cost effectiveness to choose the most effective and efficient type of therapy. This study aims to evaluate the differences in effectiveness and cost of anemia therapy in patients with CKD and determine the regimen that most affects the effectiveness of treatment costs. Data collection was conducted retrospectively based on medical records and patient financial records at Al-Ihsan Hospital by purposive nonrandom sampling in the period July-December 2023. Cost-effectiveness analysis was conducted by calculating the Average Cost Effectiveness Ratio (ACER), Incremental Cost Effectiveness Ratio (ICER) and sensitivity analysis. The results showed that the average increase in Hb in the group of patients given blood transfusion therapy was higher (7.28%) compared to the Hemapo® (1.12%) and Renogen® (1.70%) groups. The ACER value in the blood transfusion group was lower than the other two groups at Rp 4.702.512. Based on the ICER value, the Renogen® group has a lower value of Rp 38.572. The conclusion of this study is that blood transfusion is the most cost-effective therapy group and based on the results of sensitivity analysis shows that the Hemapo® therapy group is the therapy regimen that most affects cost-effectiveness.
| Item Type: | Thesis (Skripsi) |
|---|---|
| Uncontrolled Keywords: | Anemia, Analisis Efektivitas Biaya, Average Cost Effectiveness Ratio (ACER), Incremental Cost Effectiveness Ratio (ICER) ----- Anemia, Cost Effectiveness Analyis, Average Cost Effectiveness Ratio (ACER), Incremental Cost Effectiveness Ratio (ICER) |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine |
| Divisions: | Program Studi S1 Farmasi |
| Depositing User: | pustakawan - - |
| Date Deposited: | 28 Aug 2024 01:43 |
| Last Modified: | 28 Aug 2024 01:43 |
| URI: | http://repository.stfi.ac.id/id/eprint/1073 |
Actions (login required)
 |
View Item |
